Variable | Â | Virological status | COR (95% CI) | AOR (95% CI) | |
---|---|---|---|---|---|
Virological suppression | No virological suppression | ||||
Current age (years) | ≤ 30 | 44 | 15 | 1.00 | 1.00 |
31–45 | 137 | 35 | 1.33(0.67, 2.67) | 2.06 (0.93, 4.53) | |
> 45 | 84 | 8 | 3.58 (1.4, 9.10) | 5.99 (2.12, 16.91)* | |
Age at enrollment (year) | ≤ 25 | 61 | 20 | 1.00 | - |
26–40 | 150 | 35 | 1.40 (0.75, 2.62) | - | |
> 40 | 54 | 3 | 5.90 (1.66, 20.96) | - | |
Duration since ART initiation (year) | 1–5 | 78 | 19 | 1.00 |  |
6–10 | 123 | 28 | 1.17 (0.55 2.48) | - | |
> 10 | 64 | 11 | 1.37 (0.60, 3.10) | - | |
Baseline CD4 count (cell/mm3) | < 200 | 143 | 33 | 1.00 | - |
200–499 | 94 | 17 | 1.27 (0.67, 2.42) | - | |
> 499 | 28 | 8 | 0.80 (0.34, 1.93) | - | |
CD4 count at VL testing (cell/mm3) | < 350 | 70 | 36 | 1.00 | 1.00 |
350–499 | 55 | 11 | 2.57 (1.20, 5.51) | 2.56 (1.14, 5.75)* | |
> 499 | 140 | 11 | 6.54 (3.14, 13.63) | 7.71 (3.48, 17.09)* | |
Baseline anemic status | Non-anemic | 158 | 28 | 1.00 | - |
Anemic | 107 | 30 | 0.63 (0.35, 1.11) | - | |
Baseline functional status | Working | 228 | 49 | 1.00 | - |
Ambulatory and bedridden | 37 | 9 | 0.88 (0.40, 1.94) | Â | |
Baseline BMI (kg/m2) | < 18.5 | 113 | 26 | 1.00 | - |
≥ 18.5 | 152 | 32 | 1.09 (0.61, 1.93) |  | |
Baseline WHO stage | Stages I and II | 77 | 11 | 1.00 | - |
Stage III | 154 | 37 | 0.59 (0.28, 1.23) | - | |
Stage IV | 34 | 10 | 0.48 (0.18, 1.25) | - | |
Initial regimen | D4T-3TC-based | 27 | 7 | 1.00 | - |
AZT-3TC-based | 118 | 25 | 1.22 (0.48, 3.12) | - | |
TDF-3TC-based | 120 | 26 | 1.19 (0.47, 3.04) | - |